Does a Five-Minute Urine Cannabis Assay Measure Impairment?
Speed and analytical accuracy do not turn a urine cannabis screen into an impairment test. A portable microfluidic assay can improve specimen screening while leaving the central forensic question—what the person could do at the relevant time—unanswered.
What the new platform measured
Ko and colleagues developed a fluorescence-based microfluidic system for several urinary drugs and metabolites. Its cannabinoid target was THC-COOH, the carboxy metabolite of THC. The study evaluated standards and authentic urine specimens, including a total set of 141 specimens across the studied drug categories.
The paper reports rapid detection and favorable analytical performance in the evaluated samples. This is evidence about a laboratory device’s ability to classify specimens under its validation conditions. It is not a controlled comparison of impaired and unimpaired drivers.
Identify the denominator
The 141 specimens did not all represent independent THC-positive people. They included drug-free controls and different drug categories. A sensitivity or specificity figure must be tied to the correct analyte, comparator, cutoff, and number of specimens. Accuracy across a selected validation set also does not automatically establish the probability that a positive result is correct in a different testing population.
Why the matrix changes the interpretation
Urinary THC-COOH is not a measurement of whole-blood parent THC. It supplies information concerning exposure and elimination, not a direct reading of psychoactive effect. The platform’s fluorescence measurement does not identify the exact consumption time or measure driving performance simply because it produces an answer quickly.
What a case review should request
Obtain the specific device version, cannabinoid target, decision threshold, raw output, controls, and validation near the cutoff. Determine whether confirmation was performed with an appropriate compound-specific method. Ask whether the evidence offered concerns the analytical identification, the likely exposure history, or the person’s functional capacity.
The study’s useful contribution is a potentially practical screening workflow. Applying that contribution to an impairment dispute requires separate behavioral and timing evidence. Neither a positive screen nor favorable device validation fills those gaps.
Related evidence
See our related analysis of toxicology evidence and its limits.
Primary research
On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine. ACS Omega, 2026. DOI: 10.1021/acsomega.5c11027.
